GlassScriptPhysician profile
Julian Bernal
NPI 1235612839
$3,654.95
in general payments reported to CMS, 2019-2025
10 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $1,376 · 2023: $868 · 2024: $992 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $1,523.55 | 2022-2024 | Na, Fibergraft Aeridyan Matrix, Tfn-Advance |
| Zimmer Biomet Holdings, INC. | $1,199.00 | 2021-2023 | Quattro, Comprehensive |
| Smith+Nephew, INC. | $395.01 | 2021-2024 | Renasys Touch, Pico 14 |
| Tela Bio, INC. | $145.16 | 2022 | |
| Amgen INC. | $121.87 | 2024 | |
| Sanara Medtech INC. | $117.30 | 2025 | Celleraterx |
| Boston Scientific Corporation | $61.82 | 2022-2025 | General - Hemostasis |
| Ethicon US, LLC | $49.89 | 2024 | Dermabond Prineo |
| Pacira Pharmaceuticals Incorporated | $22.08 | 2024 | Exparel, Iovera, Zilretta |
| Pacira Therapeutics, INC. | $19.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Bernal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.